MORRISTOWN, N.J.--(BUSINESS WIRE)--Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014.
Business Update
“The second quarter of 2014 saw tremendous progress toward Pernix’s transformation to profitability of its base business. While we expect fiscal year 2014 sales from our non-promoted products to be relatively flat year over year, we expect our insomnia brand, Silenor, to be a key growth driver,” said Doug Drysdale, Chairman, President and Chief Executive Officer.
Help employers find you! Check out all the jobs and post your resume.
